Postmarketing Surveillance of Drugs: An Overview
- 1 August 1989
- journal article
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 2 (4) , 231-238
- https://doi.org/10.1177/089719008900200406
Abstract
The complete safety profile of a drug cannot be made before marketing because of the limited scope of the controlled clinical trials. Postmarketing surveillance (PMS) is the collection and analysis of information about a drug after it has been marketed. A PMS system ideally must be able to detect a rare event, determine its incidence, and validate the causality. Because an ideal system has not been devised, a combination of methods is used. The advantages and limitations of various methods of adverse drug reaction (ADE) reporting are described, and problems and concerns associated with ADE reporting are discussed. Postmarketing surveillance will continue to benefit from spontaneous reporting of ADEs by clinicians (ie, literature reports, reports to manufacturers and national regulatory agencies) to detect rare events and will be complemented by the selective use of formal PMS methods in appropriate circumstances. Increased clinician awareness of serious, potentially drug-related events together with comprehensive and complete reporting of these events will begin to address the problems of underreporting, assessment of causality, and misclassification of events.Keywords
This publication has 31 references indexed in Scilit:
- Bias in analytic researchPublished by Elsevier ,2004
- The Promise of PharmacoepidemiologyAnnual Review of Pharmacology and Toxicology, 1987
- Adverse-Drug-Reaction MonitoringNew England Journal of Medicine, 1986
- IS BETTER FEEDBACK A MAJOR STIMULUS TO SPONTANEOUS ADVERSE REACTION MONITORING?The Lancet, 1984
- Phase IV Research by Pharmaceutical CompaniesPharmacopsychiatry, 1984
- Identification of adverse reactions to new drugs. IV--Verification of suspected adverse reactions.BMJ, 1983
- Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems.BMJ, 1983
- Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays?BMJ, 1983
- Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays?BMJ, 1983
- Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?BMJ, 1983